UMMS Affiliation

School of Medicine

Publication Date

2021-01-11

Document Type

Article

Disciplines

Dermatology | Skin and Connective Tissue Diseases | Substance Abuse and Addiction

Abstract

Hyperhidrosis occurs when sweating is excessive for thermoregulatory purposes, which may result in decreased quality of life and emotional stress for patients.Classified as primary and secondary, secondary hyperhidrosis is often related to an underlying cause. Certain medications have been reported to induce hyperhidrosis, including selective serotonin reuptake inhibitors, tricyclic antidepressants, and opioid agonists. We present the case of a woman with a history of opioid use disorder who experienced hyperhidrosis in the setting of partial opioid agonist and opioid antagonist therapy (buprenorphine-naloxone), who was treated successfully with oral oxybutynin 5 mg daily.

Keywords

buprenorphine-naloxone, hyperhidrosis, opioid agonists, opioid antagonists, opioid use disorder, oxybutynin, suboxone

Rights and Permissions

Copyright © 2021 by the American Academy of Dermatology, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

DOI of Published Version

10.1016/j.jdcr.2020.12.031

Source

McCormack L, Ponce J, Chatterjee A, Tan JK. Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis. JAAD Case Rep. 2021 Jan 11;10:22-24. doi: 10.1016/j.jdcr.2020.12.031. PMID: 33732840; PMCID: PMC7941000. Link to article on publisher's site

Journal/Book/Conference Title

JAAD case reports

Related Resources

Link to Article in PubMed

PubMed ID

33732840

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS